

Fund Details

Fund Ticker	GNRX
Intraday NAV (IIV)	GNRXIV
Index Ticker	IGNRXT
Total Net Assets (\$M)	3.13
Options	Expected
Exchange	NASDAQ
Commencement	01/12/16

Fund Data

Number of Holdings	39
Currency	USD
Price/Earnings Ratio*	21.83
Price/Book Ratio*	2.49
Weighted Avg. Market Cap (\$M)	\$36,034
30-Day SEC Yield*	-0.10%
NAV: 52 Week High/Low	\$26.41/\$19.83

*30-Day SEC Yield is based on the most recent 30-day period and reflects the investment income earned after deducting a fund's expenses for the period. This yield does not necessarily reflect the yield that an investor will receive. Distributions may vary from time to time. A weighted harmonic average is used to calculate this metric. Price/Book Ratio is the price of a security divided by the book value per share of the security. Price/Earnings Ratio is the price of a security divided by the last twelve months earnings per share of the security.

Fees and Expenses*

Management Fee	0.50%
Other Expenses	2.44%
Gross Expense Ratio	2.94%
Fee Waivers and Expense Reimbursement	-2.37%
Net Expense Ratio	0.57%

*Expenses for GNRX are capped contractually at 0.55% until February 1, 2019. Cap excludes acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses.

Fund Description

VanEck Vectors[®] Generic Drugs ETF (GNRX) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics & New Pharma Index (IGNRXT), which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry.

Top 10 Holdings

Holding Name	Ticker	% of Net Assets
Pfizer Inc	PFE US	10.09
Celltrion Inc	068270 KS	7.78
Iqvia Holdings Inc	IQV US	7.76
Lonza Group Ag	LONN SW	6.37
Teva Pharmaceutical Industries Ltd	TEVA US	5.01
Sun Pharmaceutical Industries Ltd	SUNP IN	4.53
Mylan Nv	MYL US	4.53
Kyowa Hakko Kirin Co Ltd	4151 JP	3.56
Cspc Pharmaceutical Group Ltd	1093 HK	2.94
Taisho Pharmaceutical Holdings Co Ltd	4581 JP	2.89
Top 10 Total		55.46

These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Performance History: Average Annual Total Returns* (%)

Month End as of 12/31/18	1 MO	3 MO	YTD	1 YR	3 YR	5 YR	10 YR	LIFE 01/12/16
GNRX (NAV)	-13.61	-17.77	-14.84	-14.84	--	--	--	-5.57
GNRX (Share Price)	-14.37	-18.35	-14.79	-14.79	--	--	--	-5.78
IGNRXT (Index)	-13.51	-17.71	-14.51	-14.51	-6.61	--	--	-4.92
Performance Differential (NAV - Index)	-0.10	-0.06	-0.33	-0.33	--	--	--	-0.65

Quarter End as of 12/31/18	1 MO	3 MO	YTD	1 YR	3 YR	5 YR	10 YR	LIFE 01/12/16
GNRX (NAV)	-13.61	-17.77	-14.84	-14.84	--	--	--	-5.57
GNRX (Share Price)	-14.37	-18.35	-14.79	-14.79	--	--	--	-5.78
IGNRXT (Index)	-13.51	-17.71	-14.51	-14.51	-6.61	--	--	-4.92
Performance Differential (NAV - Index)	-0.10	-0.06	-0.33	-0.33	--	--	--	-0.65

*Returns less than one year are not annualized.

In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Vectors Generic Drugs ETF would have been -3.11% on 12/31/18.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Performance information for the Fund reflects temporary waivers of expenses and/or fees. Had the Fund incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Fund will fluctuate so that an investor's shares, when sold, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Fund returns reflect dividends and capital gains distributions. Net asset value (NAV) per share is calculated by subtracting total liabilities from the total assets, then dividing by the number of shares outstanding. Share price is the last price at which shares were traded on the Fund's primary listing exchange. Performance current to the most recent month end is available by calling 800.826.2333 or by visiting vaneck.com. Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Certain indices may take into account withholding taxes. Investors can not invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.

GNRX VanEck Vectors Generic Drugs ETF


As of December 31, 2018

Top 10 Countries

Country	% of Net Assets
UNITED STATES	36.84
INDIA	18.39
SOUTH KOREA	9.30
CHINA	8.67
JAPAN	8.21
SWITZERLAND	6.37
ISRAEL	5.01
JORDAN	1.74
INDONESIA	1.63
SOUTH AFRICA	1.41
Total	97.58

Sector Weightings

Sector	% of Net Assets
Health Care	97.2
Materials	2.8
Other/Cash	0.0



An investment in the Fund may be subject to risks which include, among others, investing in the pharmaceutical sector, equity securities, special risk considerations of investing in Asian and European issuers, depositary receipts, foreign securities, emerging market issuers, foreign currency, medium-capitalization companies, market, operational, index tracking, passive management, cash transactions, authorized participant concentration, no guarantee of active trading market, trading issues, fund shares trading, premium/discount risk and liquidity of fund shares, non-diversified, and concentration risks. Foreign and emerging markets investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, changes in currency exchange rates, unstable governments, and limited trading capacity which may make these investments volatile in price or difficult to trade. Medium-capitalization companies may be subject to elevated risks. The Fund's assets may be concentrated in a particular sector and may be subject to more risk than investments in a diverse group of sectors.

Indxx Global Generics & New Pharma Index (the "Index") is the exclusive property of Indxx, LLC. Indxx, LLC uses its best efforts to ensure that the Index is calculated correctly. Indxx, LLC has no obligation to point out errors in the Index to third parties. VanEck Vectors Generic Drugs ETF is not sponsored, endorsed, sold or promoted by Indxx, LLC and Indxx, LLC makes no representation regarding the advisability of investing in VanEck Vectors Generic Drugs ETF.

Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units" and otherwise can be bought and sold only through exchange trading. Shares may trade at a premium or discount to their NAV in the secondary market. You will incur brokerage expenses when trading Fund shares in the secondary market. Past performance is no guarantee of future results. Returns for actual Fund investments may differ from what is shown because of differences in timing, the amount invested, and fees and expenses.

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus, which contain this and other information, call 800.826.2333 or visit vaneck.com. Please read the prospectus and summary prospectus carefully before investing.

This content is published in the United States for residents of specified countries. Investors are subject to securities and tax regulations within their applicable jurisdictions that are not addressed on this content. Nothing in this content should be considered a solicitation to buy or an offer to sell shares of any investment in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction, nor is it intended as investment, tax, financial, or legal advice. Investors should seek such professional advice for their particular situation and jurisdiction.

Van Eck Securities Corporation, Distributor | 666 Third Avenue | New York, NY 10017

FUND TICKER: GNRX 800.826.2333 VANECK.COM